GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advaxis Inc (OTCPK:ADXS) » Definitions » Free Cash Flow per Share

Advaxis (Advaxis) Free Cash Flow per Share

: $-7.74 (TTM As of Mar. 2023)
View and export this data going back to 2005. Start your Free Trial

Advaxis's Free Cash Flow per Share for the three months ended in Mar. 2023 was $-1.53. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $-7.74.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the FCF Growth Rate using Free Cash Flow per Share data.

The historical rank and industry rank for Advaxis's Free Cash Flow per Share or its related term are showing as below:

ADXS's 3-Year FCF Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 2.7
* Ranked among companies with meaningful 3-Year FCF Growth Rate only.

Advaxis Free Cash Flow per Share Historical Data

The historical data trend for Advaxis's Free Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advaxis Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Free Cash Flow per Share
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,510.93 -196.89 -29.74 -9.85 -8.51

Advaxis Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Mar23
Free Cash Flow per Share Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.31 -2.42 -2.16 -1.64 -1.53

Competitive Comparison

For the Biotechnology subindustry, Advaxis's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advaxis Price-to-Free-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Advaxis's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Advaxis's Price-to-Free-Cash-Flow falls into.



Advaxis Free Cash Flow per Share Calculation

Free Cashflow per Share is the amount of Free Cashflow per outstanding share of the company's stock.

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

Note: GuruFocus does not calculate Free Cash Flow Per Share when Capital Expenditure is 0.

Advaxis's Free Cash Flow Per Share for the fiscal year that ended in Oct. 2022 is calculated as

Free Cash Flow Per Share(A: Oct. 2022 )
=(Cash Flow from Operations+Capital Expenditure)/Shares Outstanding (Diluted Average)
=(-15.284+-0.201)/1.819
=-15.485/1.819
=-8.51

Advaxis's Free Cash Flow Per Share for the quarter that ended in Mar. 2023 is calculated as

Free Cash Flow Per Share(Q: Mar. 2023 )
=(Cash Flow from Operations+Capital Expenditure)/Shares Outstanding (Diluted Average)
=(-6.741+0)/4.405
=/4.405
=0.00

Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advaxis  (OTCPK:ADXS) Free Cash Flow per Share Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.

Therefore, as of Oct22, Advaxis's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Oct22)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/1.25+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.


Advaxis Free Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Advaxis's Free Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Advaxis (Advaxis) Business Description

Traded in Other Exchanges
N/A
Address
9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 8540
Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.
Executives
Roy Golan officer: Chief Financial Officer 24 GOLDA MEIR ST., HOLON L3 5840425
Yuval Cabilly director C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348
Pini Orbach director C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Israel Biotech Fund Ii, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Israel Biotech Fund Gp Partners Ii, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Murray A Goldberg director 2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Vered Bisker-leib director C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Amoon Growth Fund Limited Partnership 10 percent owner 34 YERUSHALAYIM RD., RAANANA L3 4350110
Israel Biotech Fund Gp Partners, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Yair Chaim Schindel 10 percent owner YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
I.b.f. Management Ltd. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Igor Gitelman officer: Chief Accounting Officer 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070

Advaxis (Advaxis) Headlines

From GuruFocus

Advaxis and Ayala Pharmaceuticals Complete Merger

By Stock market mentor Stock market mentor 01-19-2023

Advaxis, Inc. Announces 1-for-80 Reverse Stock Split

By GuruFocusNews GuruFocusNews 06-03-2022

Advaxis Announces Publication of ADXS-PSA Data in The Oncologist

By GuruFocusNews GuruFocusNews 04-08-2022

Advaxis, Inc. Announces 1-for-80 Reverse Stock Split

By GuruFocusNews GuruFocusNews 07-07-2022